Beta
Cardiac glycosides (e.g. Digoxin)
medication Under reviewCardiac glycosides are a class of plant-derived compounds that increase the force of heart muscle contraction and slow conduction through the atrioventricular node. Digoxin, extracted from the foxglove plant Digitalis lanata, is the most commonly used cardiac glycoside in modern medicine. It is taken orally or intravenously as a prescription drug, primarily for specific heart rhythm disorders and certain types of heart failure. Cardiac glycosides work mainly by inhibiting the sodium–potassium ATPase pump in cell membranes. This inhibition increases intracellular sodium, which in turn reduces the activity of the sodium–calcium exchanger, leading to higher intracellular calcium in cardiac muscle cells. The increased calcium enhances contractility, while effects on the autonomic nervous system and conduction tissue slow heart rate and increase vagal tone. Beyond these classical effects, digoxin and related glycosides have been shown in experimental settings to modulate neurohormonal activation and various cellular signaling pathways. Their clinical applications are tightly constrained by a narrow therapeutic window and substantial toxicity risk, so they are used in carefully selected cardiac patients rather than as a general-purpose supplement for healthy individuals.
Research summary
The clinical research base for digoxin and other prescription cardiac glycosides is extensive, but it almost exclusively involves patients with heart failure, atrial fibrillation, or other cardiovascular diseases rather than healthy volunteers. Large randomized controlled trials and guideline-directed analyses show that in patients with systolic heart failure and normal sinus rhythm, digoxin does not reduce overall mortality but can reduce hospitalizations for worsening heart failure when used on top of standard therapies. In atrial fibrillation, digoxin is used for ventricular rate control in selected patients, with mixed observational data regarding long-term mortality that are confounded by disease severity. In healthy humans, there is no evidence supporting cardiac glycosides as a performance, longevity, or wellness supplement, and their narrow therapeutic index makes unsupervised use hazardous. Toxicity can occur at or slightly above therapeutic plasma concentrations and is influenced by kidney function, electrolyte balance, drug interactions, and age. Because of these risks and the absence of benefit data in healthy populations, cardiac glycosides are strictly prescription medications and should not be considered supplemental agents for otherwise healthy individuals.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!